Oxford Brain Diagnostics Ltd. news
Approximately 201 patients will be enrolled to study the XPro™ intervention. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro™ in patients with mild AD.
Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that their Cortical Disarray Measurement (CDM®) has been appointed as a secondary outcome measur
Oxford Brain Diagnostics team are really looking foward to attending ADPD2022 this year. We invite all our colleagues, friends and collaborators to listen into our talk. Its starts at 18:45 (CET) 17th March 2022. - `Novel in vivo cortical diffusion MRI measures correlate with classical neuropathology across the #alzheimers continuum in an autopsy confirmed cohort`.
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have established a research collaboration with Principal Investigator Dr Takashi Nakajima, MD, PhD at Niigata Hospital and Dr Kazuo Shigematsu at Minami Kyoto National Hospital. In Japan, clinical MRI scanners are available for the diagnosis and evaluation of dementia. Brain imaging by MRI is available for patients with dement
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have been awarded funding by the National Institute for Health Research (NIHR) to assess CDM® as a novel and promising tool to identify and predict disease progression amongst patients presenting with mild cognitive impairment due to Alzheimer’s disease. This multi-centre project, led by Oxford Brain Diagnostics, inc
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease
Oxford Brain Diagnostics’ first product from its software platform seeks to be a breakthrough in the